A decade of promises in personalised cancer medicine: is the honeymoon over?

Robyn L Ward
Med J Aust 2014; 200 (3): . || doi: 10.5694/mja14.00018
Published online: 17 February 2014

Substantive benefits of personalised medicine continue to elude us

For more than a decade now, we have been promised that genetic knowledge would personalise our health care. The media has told us that this information will be our own medical crystal ball, and if we fail to adhere to personalised disease prevention plans we can receive targeted medicines to treat our disease. Support for this future vision of personalised medicine has been unwavering, despite its reported slow progress.1,2

  • Prince of Wales Clinical School, University of New South Wales, Sydney, NSW.


Competing interests:

I am a member of the Pharmaceutical Benefits Advisory Committee and chair of the Medical Services Advisory Committee and Human Genetics Advisory Committee. The views expressed here do not represent the views of these committees.

  • 1. What happened to personalized medicine? Nat Biotechnol 2012; 30: 1.
  • 2. Micheel CM, Nass SJ, Omenn GS, editors. Evolution of translational omics: lessions learned and the path forward. Washington, DC: National Academies Press, 2012.
  • 3. Baggerly KA, Coombes KR. What information should be required to support clinical “omics” publications? Clin Chem 2011; 57: 688-690.
  • 4. United Stated Institute of Medicine. Genome-based diagnostics: demonstrating clinical utility in oncology. Workshop summary. Washington DC: National Academies Press, 2013.
  • 5. Saltz LB, Meropol NJ, Loehrer PJ Sr, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-1208.
  • 6. Adelstein BA, Dobbins TA, Harris CA, et al. A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer. Eur J Cancer 2011; 47: 1343-1354.
  • 7. Lewis JR, Lipworth WL, Kerridge IH, Day RO. The economic evaluation of personalised oncology medicines: ethical challenges. Med J Aust 2013; 199: 471-473. <MJA full text>
  • 8. Douillard JY, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013; 369: 1023-1034.
  • 9. Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer Res 2012; 72: 4875-4882.
  • 10. Oyan B. Why do targeted agents not work in the adjuvant setting in colon cancer? Expert Rev Anticancer Ther 2012; 12: 1337-1345.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.